What advances coming in 2018 have the most potential to affect the care of our patients with advanced NSCLC? H. Jack West, MD, offers his thoughts.
What is the best approach for our patients with progressive ALK-positive NSCLC? Here I share my thoughts based on the latest available evidence on using ALK inhibitors in the setting of progressive disease.
How will the new dosing schedule for nivolumab in NSCLC affect our current practice? Here are my thoughts.
The optimal treatment of newly diagnosed patients with advanced NSCLC is changing. Here is how new findings reported at AACR 2018 are affecting my clinical practice.
With checkpoint inhibitors now moving into both unresectable stage III and first-line metastatic NSCLC, how should we approach managing patients who progress on these agents in earlier disease settings? Read my thoughts on these new clinical challenges.
How do the latest reported findings from ALTA-1L affect our decisions in first-line ALK-positive NSCLC?
Leora Horn, MD, MSc, FRCPC, provides insight on the optimal treatment of patients with advanced NSCLC and both an oncogenic driver mutation and high PD-L1 tumor expression.
Leora Horn, MD, MSc, FRCPC, provides insight on the optimal management of patients with progressive advanced squamous NSCLC with unknown PD-L1 expression.
Gain expert insight on recent data informing the optimal treatment of patients with metastatic lung adenocarcinoma and no detectable tumor PD-L1 expression.
Watch this on-demand video for expert perspective on how to apply the latest clinical data to treating patients with metastatic squamous NSCLC and low tumor PD-L1 expression.
Download this simple resource providing an overall summary of advanced NSCLC care including an up-to-date treatment algorithm, toxicity management, and a listing of key enrolling clinical trials.
In this Virtual Presentation, Melissa L. Johnson, MD, discusses current expert treatment recommendations for 3 key patient scenarios in the rapidly evolving therapeutic landscape of advanced NSCLC. Afterwards, download the slides and use the treatment decision tool for your practice.
In this downloadable slideset, Melissa L. Johnson, MD, presents recent practice changing data that impacts the management of patients with advanced NSCLC. Click here to use our online tool to see how to select optimal therapy for your patients.
Get expert insights on how the latest clinical data inform management of challenging NSCLC cases, including with intermediate PD-L1 expression, high PD-L1 levels and a BRAF V600E mutation, EGFR-mutated disease progressing on erlotinib, and metastatic disease with undetectable PD-L1 progressing on chemotherapy plus pembrolizumab.
In this downloadable slideset, see expert recommendations for challenging lung cancer case scenarios and the evidence for those recommendations. Click here to use our updated online tool to see how to select optimal therapy for your patients with lung cancer.
Examine evolving best treatment practices and recent clinical trial findings on immunotherapy approaches for unresectable stage III NSCLC, with expert commentary and interactive cases.
Examine recent clinical trial data on checkpoint inhibitors for unresectable stage III NSCLC in this expert-authored downloadable slideset.
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with unresectable stage III or metastatic non-small-cell lung cancer with 5 world-renowned experts.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.